Mevalonate Metabolism in Cancer Stemness and Trained Immunity

Mevalonate metabolism provides cancer and immune cells with diverse products to ensure cell functionality. Similar metabolic reprogramming that raises mevalonate metabolism to higher levels appears to drive both, epithelial mesenchymal transition (EMT) of cancer cells, a reverse differentiation program that generates cancer cells with stem cell properties, and immune cell training for increased responsiveness to secondary stimulation. In this review, we address how mevalonate metabolism supports cancer development and stemness on the one hand, and on the other promotes immune responsiveness. In view of this dual nature of mevalonate metabolism, strategies to manipulate this metabolic pathway as part of anti-cancer therapies require careful analysis of risks versus benefits.

Abstract licence: CC BY

40 more references, whose wording the paper’s licence keeps private.

• Statins: a repurposed drug to fight cancer · 2021

• The Mevalonate Pathway, a Metabolic Target in Cancer Therapy · 2021

• Targeting SREBP-2-Regulated Mevalonate Metabolism for Cancer Therapy · 2020

• Trained Immunity-Based Vaccines: A New Paradigm for the Development of Broad-Spectrum Anti-infectious Formulations · 2018

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.